Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.
about
CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent MannerNewcastle disease virus-like particles: preparation, purification, quantification, and incorporation of foreign glycoproteinsBALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV.Assembly and biological and immunological properties of Newcastle disease virus-like particles.Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus.Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.Ginseng diminishes lung disease in mice immunized with formalin-inactivated respiratory syncytial virus after challenge by modulating host immune responses.Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells.Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in childrenMammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory TractMurine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F proteinAlum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune CellsRespiratory syncytial virus-like nanoparticle vaccination induces long-term protection without pulmonary disease by modulating cytokines and T-cells partially through alveolar macrophages.Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination.Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in miceCotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomainsProtection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin.Plant-derived virus-like particles as vaccinesVaccines against respiratory syncytial virus: The time has finally come.Sendai virus as a backbone for vaccines against RSV and other human paramyxovirusesLactobacillus plantarum DK119 as a probiotic confers protection against influenza virus by modulating innate immunityRecent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.The Respiratory Syncytial Virus Phosphoprotein, Matrix Protein, and Fusion Protein Carboxy-Terminal Domain Drive Efficient Filamentous Virus-Like Particle Formation.Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch.Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.Virus-like particles in vaccine development.Respiratory syncytial virus: current progress in vaccine development.Bioengineering virus-like particles as vaccines.Recent advances in the development of subunit-based RSV vaccines.New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.Expression and Purification of Virus-like Particles for Vaccination.
P2860
Q27303940-AE8E0D09-26FA-4D0A-9BF8-A214B9871713Q33677863-F8C86FA9-EE65-40AE-AE95-4E0F142D9D81Q33798426-D0A3783F-0527-4806-B91B-600D913B5D4EQ33826688-855987D1-0D83-43EC-94F9-D9E1B63C5978Q33865400-FFE371C3-8E78-44A8-A8EA-E4AA01A9D3A2Q34059404-212A712B-4122-4251-99BF-AE07B0660044Q34224973-DB39DD20-6120-4DFD-9CE4-462C3D60A0E6Q34322342-B03D4202-60D2-4D28-9302-DBEF37815254Q34440116-D3C5CCEE-B6D3-470E-A6A6-05614D2BBC6CQ34457791-CF9C43EE-9278-4F8C-8625-DC2B43D96647Q34504791-F7BDED3E-811C-4021-87F8-FA42F0CB94FFQ34791209-5874D3B2-31A7-4A35-A16F-67DCCE1C84D3Q34990420-07A77F18-3F23-46E3-8AA1-CF43849DA5A1Q35188476-C1638EFA-92F4-49B2-8A69-642A9972A153Q35595950-81F142A1-0112-4465-838A-A04F7C496AE6Q35690781-5DB4E88A-ADE4-4169-BF54-3F590249422DQ35745343-E0DB6522-448F-42E5-B1A9-73BE04419334Q35808047-B55ED576-C44F-4462-9579-432433C578C6Q35867712-0D64E9EA-5F3B-4A51-8D31-A936D90630DBQ35887649-BE15686A-F360-419A-9242-3A3DF4BB4012Q36106575-DC240DB5-B162-4063-B802-CEC23166D032Q36256989-7C8FE15D-CC70-4363-94D4-564ADA09286EQ36281893-9377F351-3A9D-4235-9191-689AC5BF0686Q36363325-D940D65A-EB51-408A-87B8-C4C92D00D9EAQ36739674-97E98319-3823-4608-A3B5-F548567531BEQ36888029-BB7E0157-7709-45A1-B20A-2D5CE0C8DE74Q37018347-9B629CDE-8FF9-414B-8A0C-78A0A94D5E89Q37118707-9A6AE0B2-7BB0-4FDF-9CAF-EA0ACBABDE29Q37215818-F0B21CDC-16E6-43F2-B0FD-2965E0FBF23DQ37412509-9E7207BB-D790-4AEA-A38A-A521C99A867AQ37415410-37DEE2D6-74CE-4C85-8414-07FB8B3D9FA9Q37469592-5287C13A-245E-4D61-87D2-54C78DAEC646Q37649439-45DCBB85-695D-4D07-9068-34A07181CB53Q37745980-E47C070E-89ED-4AA0-8DF0-14017AC8D23DQ37798008-C7A54192-2726-43B6-A7D4-E73C5F9E1186Q38079432-03046FAF-8D6C-4093-9D5E-8F3D7EFF49E2Q38172045-9BFFC57E-BCB8-4241-944B-8B41930294AAQ38617302-F22557D5-A5C1-4C2B-96FB-73D19FA1DE3BQ38628928-A1F38E69-9F91-4719-8F16-CB4B83653B91Q38765283-609C7B6C-3E2D-4EF6-B28D-1ECC88295C12
P2860
Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Newcastle disease virus-like p ...... o evidence of immunopathology.
@ast
Newcastle disease virus-like p ...... o evidence of immunopathology.
@en
Newcastle disease virus-like p ...... o evidence of immunopathology.
@nl
type
label
Newcastle disease virus-like p ...... o evidence of immunopathology.
@ast
Newcastle disease virus-like p ...... o evidence of immunopathology.
@en
Newcastle disease virus-like p ...... o evidence of immunopathology.
@nl
prefLabel
Newcastle disease virus-like p ...... o evidence of immunopathology.
@ast
Newcastle disease virus-like p ...... o evidence of immunopathology.
@en
Newcastle disease virus-like p ...... o evidence of immunopathology.
@nl
P2093
P2860
P356
P1433
P1476
Newcastle disease virus-like p ...... o evidence of immunopathology.
@en
P2093
Armando E Fraire
Evelyn A Kurt-Jones
Gale Smith
Lori W McGinnes
Matthew R Murawski
Michael J Massare
Penny M Heaton
Robert W Finberg
Trudy G Morrison
P2860
P304
P356
10.1128/JVI.01709-09
P577
2009-11-04T00:00:00Z